

Product datasheet for TR302300

OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

Papillary renal cell carcinoma (PRCC) Human shRNA Plasmid Kit (Locus ID 5546)

Product data:

Product Type: shRNA Plasmids

Product Name: Papillary renal cell carcinoma (PRCC) Human shRNA Plasmid Kit (Locus ID 5546)

Locus ID: 5546

RCCP1; TPRC Synonyms:

pRS (TR20003) Vector:

E. coli Selection: Ampicillin Mammalian Cell Puromycin

Selection:

Format: Retroviral plasmids

Components: PRCC - Human, 4 unique 29mer shRNA constructs in retroviral untagged vector(Gene ID =

5546). 5µg purified plasmid DNA per construct

29-mer scrambled shRNA cassette in pRS Vector, TR30012, included for free.

NM 005973, NM 199416, NM 005973.1, NM 005973.2, NM 005973.3, NM 005973.4, RefSeq:

NM 199416.1, BC010450, BC010450.1, BC004913, BM423590

UniProt ID: 092733

Summary: This gene encodes a protein that may play a role in pre-mRNA splicing. Chromosomal

> translocations (X;1)(p11;q21) that result in fusion of this gene to TFE3 (GeneID 7030) have been associated with papillary renal cell carcinoma. A PRCC-TFE3 fusion protein is expressed in affected carcinomas and is likely associated with altered gene transactivation. This fusion protein has also been associated with disruption of the cell cycle. [provided by RefSeq, Aug

2010]

shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To

> be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u>. If you need a special design or shRNA sequence, please utilize our custom shRNA service.





Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).